Complex | |
AACDB_ID: | 3037 |
PDBID: | 6VN1 |
Chains: | JN_C |
Organism: | Homo sapiens, Human alphaherpesvirus 3 |
Method: | EM |
Resolution (Å): | 2.80 |
Reference: | 10.1038/s41467-020-17911-0 |
Antibody | |
Antibody: | 93k Fv |
Antibody mutation: | No |
INN (Clinical Trial): | |
Antigen | |
Antigen: | Herpesvirus Envelope glycoprotein B |
Antigen mutation: | No |
Durg Target: |
Antibody
Heavy Chain: J
Mutation: NULL
>6VN1_J|Chain B[auth H], E[auth I], H[auth J]|Human monoclonal antibody 93k variable heavy chain|Homo sapiens (9606) QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNFAISWVRQAPGQGLEWMGRIMPLFVTSTYAQKFQGRVTISADASTSTAYMELSSLRSDDTAMYYCARDITAPGAAPTPLNFYGMDVWGQGTTVTVSS |
Light Chain: N
Mutation: NULL
>6VN1_N|Chain A[auth L], D[auth M], G[auth N]|Human monoclonal antibody 93k variable light chain|Homo sapiens (9606) DIQMTQSPSTLSASVGDRVTITCRASQTISTWLAWYQQTPRKAPKLMIYKASILENGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQYKSYPWTFGQGTKVEI |
Antigen
Chain: C
Mutation: NULL
>6VN1_C|Chain C[auth A], F[auth B], I[auth C]|Envelope glycoprotein B|Human alphaherpesvirus 3 (10335) MSPCGYYSKWRNRDRPEYRRNLRFRRFFSSIHPNAAAGSGFNGPGVFITSVTGVWLCFLCIFSMFVTAVVSVSPSSFYESLQVEPTQSEDITRSAHLGDGDEIREAIHKSQDAETKPTFYVCPPPTGSTIVRLEPPRTCPDYHLGKNFTEGIAVVYKENIAAYKFKATVYYKDVIVSTAWAGSSYTQITNRYADRVPIPVSEITDTIDKFGKCSSKATYVRNNHKVEAFNEDKNPQDMPLIASKYNSVGSKAWHTTNDTYMVAGTPGTYRTGTSVNCIIEEVEARSIFPYDSFGLSTGDIIYMSPFFGLRDGAYREHSNYAMDRFHQFEGYRQRDLDTRALLEPAARNFLVTPHLTVGWNWKPKRTEVCSLVKWREVEDVVRDEYAHNFRFTMKTLSTTFISETNEFNLNQIHLSQCVKEEARAIINRIYTTRYNSSHVRTGDIQTYLARGGFVVVFQPLLSNSLARLYLQELVRENTNHSPQKHPTRNTRSRRSVPVELRANRTITTTSSVEFAMLQFTYDHIQEHVNEMLARISSSWCQLQNRERALWSGLFPINPSALASTILDQRVKARILGDVISVSNCPELGSDTRIILQNSMRVSGSTTRCYSRPLISIVSLNGSGTVEGQLGTDNELIMSRDLLEPCVANHKRYFLFGHHYVYYEDYRYVREIAVHDVGMISTYVDLNLTLLKDREFMPLRVYTRDELRDTGLLDYSEIQRRNQMHSLRFYDIDKVVQYDSGTAIMQGMAQFFQGLGTAGQAVGHVVLGATGALLSTVHGFTTFLSNPFGALAVGLLVLAGLVAAFFAYRYVLKLKTSPMKALYPLTTKGLKQLPEGMDPFAEKPNATDTPIEEIGDSQNTEPSVNSGFDPDKFREAQEMIKYMTLVSAAERQESKARKKNKTSALLTSRLTGLALRNRRGYSRVRTENVTGV |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
Chain residues position delta_SASA
: residuesposition N: THR31 TRP32 TYR49 LYS50 SER52 ILE53 LEU54 GLU55 ASN56 SER67 J: GLN1 VAL2 GLY27 THR28 ASN31 ILE100 THR101 ALA102 PRO103 GLY104 ALA105 ALA106 PRO107 THR108 PRO109 LEU110 ASN111 TYR113 C: THR115 LYS116 PRO117 SER589 ASP590 ARG592 ILE593 ILE594 LEU595 GLN596 ASN597 SER615 VAL617 LEU619 ASN620 GLY621 GLY623 THR624 PHE655 HIS657 HIS658 VAL660 TYR667 GLU670 HIS674 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 6 Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 6 Å from any atom.
Interacting residues (Atom distance based)